Sonoma Pharmaceuticals
SNOA
17 hedge funds and large institutions have $91.7K invested in Sonoma Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 2 closing their positions.
236% more capital invested
Capital invested by funds: $27.3K → $91.7K (+$64.4K)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
150% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 2
21% more funds holding
Funds holding: 14 → 17 (+3)
0.06% more ownership
Funds ownership: 0.05% → 0.11% (+0.06%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$34.7K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.04K |
| 3 |
Jane Street
New York
|
+$8.05K |
| 4 |
HF
HRT Financial
New York
|
+$3.83K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$7.66K |
| 2 |
Millennium Management
New York
|
-$2.17K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$662 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$14 |
SNOA Hedge Fund Activity: Q2 2024 in Review
17 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q2 2024, worth a combined $91.7K — up 236% from $27.3K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SNOA positions and 2 closed out — a net gain of 3 holders — while 5 added to existing stakes and 2 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $34.7K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $7.66K sold.
- 17 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q2 2024, up from 14 in Q1 2024.
- Funds reported $91.7K of Sonoma Pharmaceuticals stock for Q2 2024, up 236% quarter-over-quarter.
- 5 funds opened new Sonoma Pharmaceuticals positions in Q2 2024 and 2 closed out, a net change of +3 holders.
- The largest Sonoma Pharmaceuticals buyer in Q2 2024 was Citadel Advisors, an estimated $34.7K added.
- The largest Sonoma Pharmaceuticals seller in Q2 2024 was Susquehanna International Group, an estimated $7.66K sold.
Based on aggregated 13F filings for Q2 2024.